2-(4-吗啉苯基)乙醇 | 105004-54-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 2-(4-吗啉苯基)乙醇
• 英文名称: 4-(4-Morpholinyl)benzeneethanol
• 英文别名: 2-(4-morpholin-4-yl-phenyl)-ethanol；4-Morpholinophenethyl alcohol；2-(4-morpholin-4-ylphenyl)ethanol；2-(4-morpholinophenyl)ethanol
• CAS: 105004-54-4
• 化学式: C₁₂H₁₇NO₂
• 分子量: 207.272
• InChiKey: YRTPKNDWCRKFAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-(4-吗啉苯基)乙醇 在 甲基磺酰氯 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以81%的产率得到4-morpholinophenethyl mesylate
  参考文献：
  名称：

  EP1403258

  摘要：

  公开号：
• 作为产物：
  描述：

  吗啉 、 2-(4-溴苯乙氧基)四氢-2H-吡喃 在 palladium diacetate 2-(二叔丁基膦)联苯 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 16.0h， 以95%的产率得到2-(4-吗啉苯基)乙醇
  参考文献：
  名称：

  EP1403258

  摘要：

  公开号：

文献信息

• [EN] HETEROCYCLIC KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE HETEROCYCLIQUE
  申请人：ABBOTT LAB

  公开号：WO2004076424A1

  公开（公告）日：2004-09-10

  Compounds having the formula (I) are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有公式(I)的化合物对于抑制蛋白激酶是有用的。还公开了制造这些化合物的方法、包含这些化合物的组合物以及使用这些化合物的治疗方法。
• Improved Functional Group Compatibility in the Palladium-Catalyzed Synthesis of Aryl Amines
  作者：Michele C. Harris、Xiaohua Huang、Stephen L. Buchwald

  DOI：10.1021/ol0262688

  日期：2002.8.1

  use of Pd2dba3 with bulky, electron-rich ligands 1 or 2 and LiN(TMS)2 as the base for the coupling of amines with aryl halides containing hydroxyl, amide, or enolizable keto groups is described. This protocol expands the utility of palladium-catalyzed C-N bond formation by allowing for the use of aryl halides containing these functional groups, obviating the need for protecting group manipulations

  [反应：见正文]描述了将Pd2dba3与庞大的富电子配体1或2和LiN（TMS）2用作胺与含有羟基，酰胺或可烯丙基酮基的芳基卤化物偶合的基础。通过允许使用含有这些官能团的芳基卤化物，该方案扩展了钯催化的CN键形成的应用，从而避免了对保护基团的操作。
• Palladium/Proazaphosphatrane-Catalyzed Amination of Aryl Halides Possessing a Phenol, Alcohol, Acetanilide, Amide or an Enolizable Ketone Functional Group: Efficacy of Lithium Bis(trimethylsilyl)amide as the Base
  作者：Sameer Urgaonkar、John G. Verkade

  DOI：10.1002/adsc.200404005

  日期：2004.5

  A commercially available catalyst system comprising Pd(OAc)2 or Pd2(dba)3 and the proazaphosphatrane ancillary ligand P(i-BuNCH2CH2)3N (1) for the amination of aryl halides substituted with a phenol, alcohol, acetanilide, amide or ketone group containing an enolizable hydrogen is described. The reaction is performed in the presence of LiN(SiMe3)2 as the base. Other bases tested were either less effective

  包含Pd（OAc）2或Pd 2（dba）3和原氮杂磷杂环戊烷辅助配体P（i- BuNCH 2 CH 2）3 N（1）的市售催化剂体系，用于胺化被苯酚，醇，描述了含有可烯醇化氢的乙酰苯胺，酰胺或酮基。反应在LiN（SiMe 3）2作为碱的存在下进行。所测试的其他基础不是很有效，就是完全没有功能。
• NOVEL 2,3-DIHYDRO-1H-IMIDAZO(1,2-A)PYRIMIDIN-5-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF
  申请人：Brolio Maurice

  公开号：US20120142679A1

  公开（公告）日：2012-06-07

  The invention relates to the novel materials of formula (I), where R 1 is an optionally substituted L-aryl or -heteroaryl, such that L is: an alkyl or CO, or L X, with L being an alkyl and X being O or S; R 2 is H or an alkyl; R 3 is an alkyl optionally substituted by Hal; and R 4 is Hou Hal, wherein said materials are in any isomeric form and the salts thereof, to be used as drugs.

  本发明涉及式（I）的新材料，其中R1是可选取的取代L-芳基或杂芳基，其中L是：烷基或CO，或LX，其中L是烷基，X是O或S；R2是氢或烷基；R3是可选取的Hal取代的烷基；R4是H或Hal，其中所述材料以任何异构体形式及其盐的形式用作药物。
• Dichloroaniline derivatives
  申请人：Glaxo Group Limited

  公开号：US04943591A1

  公开（公告）日：1990-07-24

  The invention provides compounds of the general formula (I) ##STR1## wherein X represents a C.sub.1-6 alkylene, C.sub.2-6 alkenylene or C.sub.2-6 alkynylene chain and Y represents a bond, or a C.sub.1-4 alkylene, C.sub.2-4 alkenylene or C.sub.2-4 alkynylene chain with the proviso that the sum total of carbon atoms in X and Y is not more than 8; Ar represents a phenyl group optionally substituted by one or more substituents selected from halogen atoms or the groups C.sub.1-3 alkyl, nitro, --(CH.sub.2).sub.q R [where R is hydroxy, C.sub.1-3 alkoxy, --NR.sup.3 R.sup.4 (where R.sup.3 and R.sup.4 each represent a hydrogen atom, or a C.sub.1-4 alkyl group, or --NR.sup.3 R.sup.4 forms a saturated heterocyclic amino group which has 5-7 ring members and optionally contains in the ring one or more atoms selected from --O-- or --S-- or a group --NH-- or --N(CH.sub.3)--), --NR.sup.5 COR.sup.6 (where R.sup.5 represents a hydrogen atom or a C.sub.1-4 alkyl group, and R.sup.6 represents a hydrogen atom or a C.sub.1-4 alkyl, C.sub.1-4 alkoxy or --NR.sup.3 R.sup.4 group), and q represents an integer from 0 to 3], --NR.sup.5 COR.sup.19 (where R.sup.5 is as defined above and R.sup.19 represents a phenyl group), --(CH.sub.2).sub.r R.sup.7 [where R.sup.7 represents --NR.sup.5 SO.sub.2 R.sup.8 (where R.sup.8 represents a C.sub.1-4 alkyl, phenyl or --NR.sup.3 R.sup.4 group), --NR.sup.5 COCH.sub.2 N(R.sup.5).sub.2 (where each of the groups R.sup.5 represents a hydrogen atom or a C.sub.1-4 alkyl group), --COR.sup.9 (where R.sup.9 represents hydroxy, C.sub.1-4 alkoxy or NR.sup.3 R.sup.4), --SR.sup.10 (where R.sup.10 is a hydrogen atom, or a C.sub.1-4 alkyl group optionally substituted by hydroxy, C.sub.1-4 alkoxy or NR.sup.3 R.sup.4), --SOR.sup.10, --SO.sub.2 R.sup.10, --CN, or --NR.sup.11 R.sup.12 (where R.sup.11 and R.sup.12 represent a hydrogen atom or a C.sub.1-4 alkyl group, at least one of which is C.sub.2-4 alkyl substituted by a hydroxy, C.sub.1-4 alkoxy or NR.sup.3 R.sup.4), and r represents an integer from 0 to 3], --O(CH.sub.2).sub.q COR.sup.9 (where q and R.sup.9 are as defined above), or --O(CH.sub.2).sub.t R.sup.13 [where R.sup.13 represents hydroxy, NR.sup.3 R.sup.4, NR.sup.11 R.sup.12 or a C.sub.1-4 alkoxy group optionally substituted by hydroxy, C.sub.1-4 alkoxy or NR.sup.3 R.sup.4, and t is an integer 2 or 3], or Ar is a phenyl group substituted by an alkylenedioxy group --O(CH.sub.2).sub.p O-- where p is 1 or 2; R.sup.1 and R.sup.2 each represents a hydrogen atom or a C.sub.1-3 alkyl group, with the proviso that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 4; and physiologically acceptable salts and solvates (e.g. hydrates) thereof. The compounds of formula (I) have a stimulant action at .beta..sub.2 -adrenoreceptors and are useful, in particular, in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

  本发明提供了一般式(I)的化合物：##STR1## 其中，X代表C.sub.1-6烷基，C.sub.2-6烯基或C.sub.2-6炔基链，Y代表键或C.sub.1-4烷基，C.sub.2-4烯基或C.sub.2-4炔基链，但X和Y中碳原子的总和不超过8；Ar代表苯基，可选地由一个或多个取代基选自卤素原子或C.sub.1-3烷基，硝基，--(CH.sub.2).sub.qR [其中R为羟基，C.sub.1-3烷氧基，--NR.sup.3R.sup.4（其中R.sup.3和R.sup.4各代表氢原子或C.sub.1-4烷基，或--NR.sup.3R.sup.4形成有5-7个环成员的饱和杂环氨基，其中环中可选地包含一个或多个原子选自--O--或--S--或--NH--或--N(CH.sub.3)--），--NR.sup.5COR.sup.6（其中R.sup.5代表氢原子或C.sub.1-4烷基，R.sup.6代表氢原子或C.sub.1-4烷基，C.sub.1-4烷氧基或--NR.sup.3R.sup.4基），q代表0至3的整数]，--NR.sup.5COR.sup.19（其中R.sup.5如上定义，R.sup.19代表苯基），--(CH.sub.2).sub.rR.sup.7 [其中R.sup.7代表--NR.sup.5SO.sub.2R.sup.8（其中R.sup.8代表C.sub.1-4烷基，苯基或--NR.sup.3R.sup.4基），--NR.sup.5COCH.sub.2N(R.sup.5).sub.2（其中每个R.sup.5代表氢原子或C.sub.1-4烷基），--COR.sup.9（其中R.sup.9代表羟基，C.sub.1-4烷氧基或NR.sup.3R.sup.4），--SR.sup.10（其中R.sup.10为氢原子或可选地由羟基，C.sub.1-4烷氧基或NR.sup.3R.sup.4取代的C.sub.1-4烷基），--SOR.sup.10，--SO.sub.2R.sup.10，--CN或--NR.sup.11R.sup.12（其中R.sup.11和R.sup.12代表氢原子或C.sub.1-4烷基，至少有一个是由羟基，C.sub.1-4烷氧基或NR.sup.3R.sup.4取代的C.sub.2-4烷基），r代表0至3的整数]，--O(CH.sub.2).sub.qCOR.sup.9（其中q和R.sup.9如上定义），或--O(CH.sub.2).sub.tR.sup.13 [其中R.sup.13代表羟基，NR.sup.3R.sup.4，NR.sup.11R.sup.12或可选地由羟基，C.sub.1-4烷氧基或NR.sup.3R.sup.4取代的C.sub.1-4烷氧基，t为2或3]，或Ar是由烷二氧基基团--O(CH.sub.2).sub.pO-取代的苯基，其中p为1或2；R.sup.1和R.sup.2各代表氢原子或C.sub.1-3烷基，但R.sup.1和R.sup.2中碳原子的总和不超过4；以及其生理上可接受的盐和溶剂（例如水合物）。式(I)的化合物在.beta..sub.2-肾上腺素受体上具有兴奋作用，并且特别适用于治疗与可逆性气道阻塞有关的疾病，如哮喘和慢性支气管炎。